dolastatin-10 and Melanoma

dolastatin-10 has been researched along with Melanoma* in 2 studies

Trials

1 trial(s) available for dolastatin-10 and Melanoma

ArticleYear
Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium.
    Investigational new drugs, 2001, Volume: 19, Issue:4

    Dolastatin-10 is a novel pentapeptide agent originally isolated from the marine mollusk Dolabella auricularia with a mechanism of antitumor activity that involves the inhibition of microtubule assembly. We performed a Phase II trial of Dolastatin-10, 400 microg/m2 in patients with advanced melanoma who had received no prior chemotherapy. Dolastatin-10 pharmokinetics were evaluated in a subset of patients following courses 1 and 2. Twelve patients were treated with a median of 2 cycles of Dolastatin-10, and no patient experienced an objective response. The only grade >2 toxicities were grade 3 neutropenia uncomplicated by infection, occurring in 4 patients following the first treatment cycle. The total systemic clearance and volume of distribution at steady-state were 2.61 +/- 1.9 L/h/m2 and 28.4 +/- 13 L/m2, respectively. Due to prolonged terminal elimination. Dolastatin-10 plasma concentrations of greater than 1 nM were sustained for 24 h in all patients studied. Dolastatin-10 is unlikely to have substantial activity in the treatment of melanoma.

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; California; Depsipeptides; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Oligopeptides; Skin Neoplasms

2001

Other Studies

1 other study(ies) available for dolastatin-10 and Melanoma

ArticleYear
Malevamide D: isolation and structure determination of an isodolastatin H analogue from the marine cyanobacterium Symploca hydnoides.
    Journal of natural products, 2002, Volume: 65, Issue:4

    Malevamide D (1), a highly cytotoxic peptide ester, and the known compound curacin D (5) were isolated from a Hawaiian sample of Symploca hydnoides. The structure of 1 was elucidated by spectroscopic analysis including NMR and high-resolution MS/MS. Partial stereochemical assignments of 1 were made by chiral HPLC analysis of acid and base hydrolysates. Malevamide D (1) demonstrated toxicity against P-388, A-549, HT-29, and MEL-28 cell lines in the subnanomolar range, while curacin D (5) was weakly cytotoxic. Malevamide D (1) is closely related to isodolastatin H (2), which was previously isolated in low yield from the sea hare Dolabella auricularia. A second Hawaiian sample of S. hydnoides yielded curacin D (5) along with the known dolastatin-10 analogue symplostatin-1 (3).

    Topics: Animals; Antineoplastic Agents, Phytogenic; Chromatography, High Pressure Liquid; Colonic Neoplasms; Cyanobacteria; Depsipeptides; Drug Screening Assays, Antitumor; Hawaii; Hydrolysis; Inhibitory Concentration 50; Leukemia P388; Lung Neoplasms; Melanoma; Mice; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Oligopeptides; Stereoisomerism; Thiazoles; Tumor Cells, Cultured

2002